O.B.System Inc.

O.B.System Inc.

TTSE:5576
3,065.00
JPY
-145.00
(-4.52%)
5.86BMarket Cap
Jan 28Next Earn
O.B.System Inc.
TSE:5576
(Tokyo Stock Exchange)

Recent

price

3,065.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
2026
TTM
JPY
2,734.22
2,885.02
2,967.66
3,014.15
3,334.77
3,735.35
- -
Revenue per Share
124.27
163
239.52
192.98
210.57
258.81
- -
Basic EPS, GAAP
135.79
97.8
143.5
10.77
187.31
135.6
- -
Free Cash Flow per Basic Share
27.57
40
50
76.38
79.9
89.92
- -
Dividend per Share
1,344.97
1,480.63
1,681.73
2,046.76
2,218.09
2,450.13
- -
Book Value per Share
1,335.64
1,472.29
1,675.22
2,042.94
2,071.15
2,004.33
- -
Tangible Book Value per Share
2
2
2
2
2
2
2
Basic Weighted Avg Shares
6,070
5,992
6,164
6,897
7,685
8,656
- -
Sales/Revenue/Turnover
6.22
6.9
8.15
8.57
7.32
7.77
- -
Operating Margin (%)
13
12
13
14
66
114
- -
Depreciation Expense
276
339
497
442
485
600
- -
Net Income, GAAP
31.55
29.85
3.85
30.18
30.22
29.08
- -
Effective Tax Rate (%)
4.54
5.65
8.07
6.4
6.31
6.93
- -
Profit Margin (%)
3,132
3,407
3,156
3,181
2,885
2,596
- -
Working Capital
- -
- -
- -
- -
- -
174
- -
LT Debt
3,063
3,371
3,829
4,712
5,114
5,699
- -
Total Equity
- -
8.84
13.15
9.56
7.8
8.35
- -
Return on Invested Capital (%)
- -
10.52
13.82
10.34
9.88
10.85
- -
Return on Capital (%)
- -
10.52
13.82
10.34
9.88
11.09
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
99
98
- -
LT Borrowings
218
174
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
6,968
5,859
6,670

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
3,551
3,834
- -
Cash, Cash Equivalents & STI
2,198
2,292
- -
Accounts Receivable, Net
1,238
1,426
- -
Inventories
40
24
- -
Total Current Liabilities
1,124
1,239
- -
Payables & Accruals
- -
- -
- -
ST Debt
99
98
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.34%
11.44%
Free Cash Flow
- -
309.5%
-27.2%
Net Income, GAAP
- -
18.38%
23.59%
Sales/Revenue/Turnover
- -
7.51%
12.64%
Total Cash Common Dividend
- -
29.51%
13.16%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
7,685
2026
- -
- -
- -
- -
8,656
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
210.57
2026
- -
- -
- -
- -
258.81
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
79.9
2026
- -
- -
- -
- -
89.92
2027
- -
- -
- -
- -
- -
Business
O.B.System Inc. is a Japan-based company specializing in system integration and development primarily for medical and clinical testing equipment, laboratory information systems, and diagnostic solutions. The company offers a comprehensive range of products and services including clinical chemistry automated analyzers, immunoassay systems, hematology analyzers, microbiology and molecular diagnostics equipment, point of care testing solutions, and laboratory information management systems. It also provides sales and maintenance of medical analyzers, biophysical chemistry instruments, research reagents, pathological systems, remote diagnostic imaging systems, image analysis systems, and life-saving/intraoperative diagnostic equipment. O.B.System serves healthcare providers, clinical laboratories, and medical institutions in over 80 countries worldwide. Founded in 1976 and headquartered in Tokyo, Japan, the company continues to expand its footprint in the global healthcare diagnostics market. Recent major developments include the acquisition of Greencat Co., Ltd. in March 2025, which reflects O.B.System’s strategic move to strengthen its technological capabilities and expand its market presence. The company has also reported ongoing steady demand in its clinical testing and system development segments, with efforts to optimize pricing and supply chain activities. These changes align with O.B.System’s focus on enhancing its integrated system solutions and service offerings to support evolving clinical testing needs and laboratory automation technologies on a global scale. The company continues to invest in scalable lab automation, clinical informatics, and comprehensive lab performance optimization services to accelerate care delivery across its broad customer base. O.B.System operates mainly in the healthcare diagnostics and medical equipment segments, targeting clinical labs, hospitals, and research institutions. The company’s product portfolio emphasizes precision diagnostic tools and information systems to improve laboratory workflow and diagnostic accuracy. Headquartered in Tokyo, O.B.System leverages global distribution channels and partnerships to maintain a competitive position in the international markets it serves. The strategic acquisition of Greencat Co., Ltd. marks a significant enhancement in its technological capabilities and service scope, supporting sustained business growth and innovation in clinical diagnostics.